Christine A. White, MD

home / authors / christine-white-md

Articles

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

T. E. Witzig;Leo I. Gordon, MD;G. A. Wiseman;S. Spies;C. Emmanouilides;Myron S. Czuczman, MD;I. W. Flinn;N. L. Barlett;J. L. Murray;B. Alkuzweny;Pratik S. Multani, MD;A. J. Grillo-Lopez, MD;Christine A. White, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) consists of an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan (MX-DTPA), which stably chelates yttrium-90 for therapy. Ibritumomab tiuxetan therapy involves pretreatment with

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

T. E. Witzig;Christine A. White, MD;Leo I. Gordon, MD;J. L. Murray;G. A. Wiseman;C. Emmanouilides;Myron S. Czuczman, MD;D. Shen;Pratik S. Multani, MD;A. J. Grillo-Lopez, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody covalently bound to the chelator tiuxetan, which can securely chelate yttrium-90. We performed a randomized controlled trial

Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas

Peter Mclaughlin, MD;Christine A. White, MD;A. J. Grillo-Lopez, MD;David G. Maloney, MD, PhD

December 1st 1998

Rituximab (IDEC-C2B8 [Rituxan]) is a chimeric anti-CD20 monoclonal antibody (MoAb) that was recently approved by the FDA for the treatment of patients with low-grade or follicular B-cell non-Hodgkin’s lymphoma. Its potential efficacy in other B-cell malignancies is currently being explored. This article reviews the mechanisms of action of rituximab, as well as preclinical data and results of the clinical trials that led to its approval. Also discussed are the mechanics of administering rituximab on the recommended weekly ´ 4 outpatient schedule. Finally, the article describes ongoing and planned trials of rituximab in other dosage schedules, in other B-cell neoplasms, and in conjunction with chemotherapy. As the first MoAb to gain FDA approval for the treatment of a malignancy, rituximab signals the beginning of a promising new era in cancer therapy. [ONCOLOGY 12(12):1763-1770, 1998]